No Detail Found!

Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience

Author(s)
Yasin Sezgin Department of Medical Oncology, Van Yuzuncu Yil University, Van, Turkiye
Ogur Karhan Department of Medical Oncology, Harran University, Sanliurfa, Turkiye
Serdar Ileri Department of Medical Oncology, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkiye
Senar Ebinc Department of Medical Oncology, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkiye
Sezai Tunc Department of Medical Oncology, Dicle University Hospital, Diyarbakir, Turkiye
Zuhat Urakci Department of Medical Oncology, Van Yuzuncu Yil University, Van, Turkiye
Abstract
Objective: To evaluate the e ciency of pemetrexed cisplatin in comparison with gemcitabine cisplatin and to validate the EORTC (European Organisation for Research and Treatment of Cancer) prognostic score in combination chemotherapytreatment for malignant pleural mesothelioma. Study Design: An observational study. Place and Duration of the Study: Department of Oncology, Dicle University Hospital, Diyarbakir, Turkiye, from October 2000 to November 2017. Methodology: Malignant pleural mesothelioma (MPM) patients with EORTC score 0- were recruited. Factors a ecting the prognosis of the disease and the e ectiveness of rst-line treatment were retrospectively analysed. EORTC prognostic score was calculated with a cut-o and survival analyses were used by the Kaplan-Meier method. Log-rank and univariable Cox regression tests were used to search for prognostic factors impact on survival. Results: Patients who received gemcitabine cisplatin treatment had a median progression-free survival (PFS) of 9 months, while those who received pemetrexed cisplatin therapy had a median PFS of 7 months.Median overall survival (OS) was 17 months in the gemcitabine cisplatin group and 18 months in the pemetrexed cisplatin group (p = 0.051).When the low-risk group was compared with the high-risk group, the median OS was found to be statistically signi cant (p = 0.009). Conclusion: The EORTC prognostic score, which is used for prognostic prediction in the period when pemetrexed is not utilised in the treatment of MPM, accurately predicts prognosis subsequent to the administration of pemetrexed in treatment. In the context of rst-line treatment, cisplatin in combination with gemcitabine and cisplatin in combination with pemetrexed demonstrated comparable e cacy with respect to both overall survival and progression-free survival.
Publication Details
Page(s) 904-909
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
prognosis, chemotherapy, Progression-free survival, Mesothelioma, Gemcitabine
0

Citations

0

Downloads

80

Views